Cuprina Fights for Nasdaq Life With Reverse Split and Appeal

SINGAPORE – May 29, 2026 – Biomedical company Cuprina Holdings (Nasdaq: CUPR) has launched a high-stakes battle to maintain its listing on the Nasdaq Stock Market, executing a reverse stock split and formally appealing a delisting determination after its shares languished below the exchange's minimum price requirement for months.

The Singapore-based firm, which operates in sectors ranging from chronic wound care to medical waste recycling, announced it completed a 1-for-8 reverse stock split on May 27. A day later, it requested a hearing before the Nasdaq Hearings Panel. The move came in direct response to a letter from Nasdaq staff notifying the company it faced delisting for failing to meet the $1.00 minimum bid price rule.

Cuprina’s proactive measures have bought it precious time. The appeal automatically stays the delisting process, allowing its securities to continue trading on the Nasdaq Capital Market pending the panel's decision. The market responded with a jolt of optimism, sending the company's newly consolidated shares soaring over 27% on May 28, trading around $2.50 by the end of the week. This surge, however, masks a year of steep declines and a precarious financial reality that led the company to this critical juncture.

A High-Stakes Gamble

Cuprina's path to the hearing panel began on November 26, 2025, when Nasdaq first issued a non-compliance notice. The company’s closing bid price had remained below $1.00 for 30 consecutive business days, triggering a 180-day grace period to regain compliance. When that deadline passed on May 26, 2026, with the stock still underwater—closing at approximately $0.27 just days prior—Nasdaq initiated delisting procedures.

By filing its appeal by the June 3 deadline, Cuprina has ensured its shares will not be suspended on June 5 as originally scheduled. The company stated it “remains committed to maintaining its Nasdaq listing” and believes the share consolidation will bring its bid price into compliance.

The 1-for-8 reverse stock split is a common, if often criticized, tool for companies in this situation. It artificially inflates the share price by reducing the number of outstanding shares—in this case, every eight shares held by an investor were converted into one. While this mechanically solves the bid price issue, it does nothing to alter the company's fundamental valuation and is often viewed by investors as a sign of underlying distress.

The Nasdaq panel will now review Cuprina's plan to maintain long-term compliance. A hearing is typically scheduled within 45 days, giving the company a brief window to present its case for why it deserves to remain on the prestigious exchange, which is vital for visibility, liquidity, and access to capital.

A Precarious Financial Picture

The need for such drastic measures is rooted in Cuprina's challenging financial performance. The company’s stock has plummeted over 90% in the past year, a reflection of negligible revenue, widening losses, and significant cash burn. Financial analyses paint a grim picture, with one report assigning the company a financial health score of just 12 out of 100, citing “significant challenges in multiple areas.”

For the first six months of 2025, Cuprina reported a mere $18,040 in revenue, a 40% drop from the previous year, which it attributed to lower sales of its cosmeceutical and wound care products. During the same period, its net loss ballooned to $1.528 million from just over half a million dollars a year prior. The company’s gross margin collapsed to a razor-thin 1.7%, indicating it is struggling to produce and sell its products profitably.

This financial strain is exacerbated by a rapid cash burn. Operating expenses surged 163% in the first half of 2025, driven by professional fees related to capital raising. Reports have highlighted a critically low cash balance and a current ratio that signals a severe inability to meet short-term obligations, noting the company is “quickly burning through cash.” Despite these figures, company leadership has projected a more optimistic 2026, anticipating it to be its “most active commercial year” with revenues potentially reaching between $1.0 million and $1.5 million.

A Pipeline of Promises

Cuprina is betting its future on a diverse pipeline of biomedical innovations that have yet to translate into significant financial returns. The company’s core business revolves around MEDIFLY, a bio-dressing for chronic wounds that uses sterile blowfly larvae for Maggot Debridement Therapy (MDT). The company is aiming for expansion in the Middle East, having recently secured product classification in Saudi Arabia where a production lab has been established.

Beyond wound care, Cuprina is branching into several other high-growth sectors. In May 2025, it completed construction of an in-vitro fertilization (IVF) media production facility in Singapore, with commercial sales projected to start by late 2026 pending regulatory approval. The company has also secured exclusive rights to a novel medical waste recycling technology for Southeast Asia and is pursuing a joint venture to develop new iodine-based antiseptic solutions.

These initiatives demonstrate ambition and a strategy to diversify, but they are capital-intensive and carry long lead times. Maintaining its Nasdaq listing is therefore not just a matter of prestige but a crucial element of its strategy to fund these future growth engines. A delisting would severely hamper its ability to attract investment and could jeopardize the commercialization of its promising, but nascent, technologies.

For now, Cuprina has successfully navigated an immediate crisis. The reverse split and subsequent appeal have provided a temporary lifeline, and the stock’s rebound suggests some investors are willing to bet on a turnaround. However, the road ahead is fraught with uncertainty. The company's fate now rests not only on the decision of the Nasdaq Hearings Panel but, more fundamentally, on its ability to transform its pipeline of promises into a profitable and sustainable business.